Defactinib - Verastem Oncology

Drug Profile

Defactinib - Verastem Oncology

Alternative Names: Defactinib hydrochloride; PF-04554878; PF-4554878; VS-6063

Latest Information Update: 08 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Cancer Research UK; Pfizer; University of California, San Diego; Verastem; Verastem Oncology; Washington University
  • Class Antineoplastics; Benzamides; Pyrazines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma; Non-small cell lung cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Phase I Cancer; Pancreatic cancer
  • Preclinical Breast cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Jun 2018 Interim pharmacodynamics, efficacy and adverse events data from a phase I/II trial in Solid tumors released by Verastem Oncology
  • 03 May 2018 Verastem is now operating as Verastem Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top